Rock Creek Pharmaceuticals, Inc. announced that it has filed a Clinical Trial Application (CTA) with the United Kingdom'sMedicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to initiate clinical trials for the continued development of its lead molecule, Anatabine Citrate. Contingent on the Company receiving CTA regulatory approval, the Company plans to conduct a Phase I trial to assess the safety, tolerability and dose escalation of Anatabine Citrate with Quotient Clinical, a UK based, contract research organization (CRO). Quotient Clinical will employ its RapidFACTTM (Rapid Formulation development And Clinical Testing) service to test novel, oral, modified release Anatabine Citrate formulations which have been developed jointly with Rock Creek Pharmaceuticals.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -.--% | -.--% |
2020 | Rock Creek Pharmaceuticals, Inc. Went Out of Business | CI |
2020 | Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 17.04K | |
+35.01% | 709B | |
+30.71% | 595B | |
-2.60% | 367B | |
+20.83% | 334B | |
+5.69% | 289B | |
+14.13% | 239B | |
+9.31% | 211B | |
-3.35% | 203B | |
+10.77% | 171B |
- Stock Market
- Equities
- RCPIQ Stock
- News Rock Creek Pharmaceuticals, Inc.
- Rock Creek Pharmaceuticals, Inc. Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations